BioNTech committed to deliver 1.8b doses of Covid-19 vaccine this year
[FRANKFURT] BioNTech said on Monday that its order backlog for delivery of Covid-19 vaccines this year together with partner Pfizer had grown to 1.8 billion doses, underscoring its role as a major global supplier of immunisation shots.
That was up from 1.4 billion doses announced in March.
Based on these delivery contracts, the company said it expects about 12.4 billion euros (S$19.98 billion) in revenue from the vaccine this year, including sales, milestone payments from partners and a share of gross profit in the partners' territories, up from a previous forecast of 9.8 billion euros.
More than 450 million doses of the two-shot vaccine known as Comirnaty were supplied globally as of May 6, 2021.
By contrast, AstraZeneca, which has pledged to deliver up to three billion vaccine doses this year, said on April 30 it had supplied more than 300 million doses so far. That includes production from partners such as the Serum Institute of India.
BioNTech and Pfizer, which have been spared the type of production setbacks that have hobbled AstraZeneca and Johnson & Johnson, have repeatedly lifted projected delivery volumes amid a global scramble to speed vaccination campaigns.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Earlier on Monday, BioNTech unveiled plans to set up a new factory in Singapore to produce several hundred million doses of its mRNA vaccines per year from 2023.
BioNTech's partner for China, Fosun Pharma, said on Sunday it would provide a factory with an annual capacity of up to one billion doses of the Covid-19 vaccine under a joint venture with BioNTech.
That followed a contract with the European Union for up to 1.8 billion doses of Covid-19 vaccines for 2021-2023, to cover booster shots, donations and reselling of doses.
BioNTech reported first-quarter total revenue of 2.05 billion euros, up from 27.7 million euros a year earlier, driven by vaccine sales, and including an estimated 1.75 billion euros from BioNTech's share of gross profit from sales in Pfizer's territories.
Quarterly net profit jumped to 1.13 billion euros, compared to a 53.4-million-euro loss in the year-earlier period.
The company said there was no evidence its current vaccine will need to be adapted to fight new virus variants, but added that it had developed strategies to address such variants should the need arise.
BioNTech reiterated that output capacity for the vaccine would reach three billion doses by the end of 2021, and more than three billion doses in 2022.
Pfizer last week said the pair was targeting production of as much as four billion doses of the shot next year, mostly for low- and middle-income countries.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Converse to cut jobs as part of Nike’s cost-savings plan
McDonald’s sells US$1 billion of bonds as debt set to mature
Blackstone-led consortium eyes snacks business of India’s Haldiram’s: sources
Cordlife shareholders vote to remove 3 directors, including co-founder Ho Choon Hou, from board
Walmart to lay off hundreds of corporate staff and relocate others: WSJ
Haidilao restaurant operator Super Hi targets US$1.38 billion valuation in US IPO